New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006

European Urology, Supplements

Volumn 6, Issue 4, 2007, Pages 396-403

  Patard, Jean Jacques ^a   Lechevallier, Eric ^b   Congregado Ruiz, Belén ^c   Montorsi, Francesco ^d  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Angiogenesis inhibitors; Cryoablation; Partial nephrectomy; Radiofrequency ablation; Renal cell cancer; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CD135 ANTIGEN; ELONGIN B; ELONGIN C; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN CUL2; PROTEIN RBX1; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TEMSIROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOABLATION; DRUG WITHDRAWAL; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; MEDICAL EXPERT; MEDICAL SOCIETY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 33846693711     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.12.014     Document Type: Review

References (40)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Available at URL: http://www.seer.cancer.gov/. Accessed 2006.
4. Cooney M.M., Remick S.C., and Vogelzang N.J. Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol 6 (2005) 357-365
5. Patel P.H., Chaganti R.S., and Motzer R.J. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94 (2006) 614-619
6. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
7. Fergelot P., Rioux-Leclercq N., Zerrouki S., et al. Relationship between VHL mutation status, tumor VEGF expression and plasma VEGF measurement in sporadic renal cell carcinoma. J Clin Oncol 24 (2006) 242 (abstract no. 4602)
8. Drucker B.J. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31 (2005) 536-545
9. Mickisch G., Carballido J., Hellsten S., et al. Guidelines on renal cell cancer. Eur Urol 40 (2001) 252-255
10. Patard J.J., Shvarts O., Lam J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (2004) 2181-2185
11. Roth T.J., Leibovich B.C., Cheville J.C., et al. Features predictive of local recurrence following nephron-sparing surgery for renal cell carcinoma. J Urol 175 (2006) 241 (abstract no. 742)
12. Trabulsi E.J., Kalra P., and Gomella L.G. New approaches to the minimally invasive treatment of kidney tumors. Cancer J 11 (2005) 57-63
13. Miller D.C., Hollingsworth J.M., Hafez K.S., et al. Partial nephrectomy for small renal masses: an emerging quality of care concern?. J Urol 175 (2006) 229 (abstract no. 708)
14. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2006. In press. doi:10.1016/j.eururo.2006.11.013.
15. Cestari A., Guazzoni G., dell'Acqua V., et al. Laparoscopic cryoablation of solid renal masses: intermediate term followup. J Urol 172 (2004) 1267-1270
16. Lee D.I., McGinnis D.E., Feld R., et al. Retroperitoneal laparoscopic cryoablation of small renal tumors: intermediate results. Urology 61 (2003) 83-88
17. Moon T.D., Lee Jr. F.T., Hedican S.P., et al. Laparoscopic cryoablation under sonographic guidance for the treatment of small renal tumors. J Endourol 18 (2004) 436-440
18. Nadler R.B., Kim S.C., Rubenstein J.N., et al. Laparoscopic renal cryosurgery: the Northwestern experience. J Urol 170 (2003) 1121-1125
19. Hegarty N.J., Gill I.S., Kaouk J.H., et al. Renal cryoablation: 5 year outcomes. J Urol 175 (2006) 351 (abstract no. 1091)
20. Memarsadeghi M., Schmook T., Remzi M., et al. Percutaneous radiofrequency ablation of renal tumors: midterm results in 16 patients. Eur J Radiol 59 (2006) 183-189
21. Sabharwal R., and Vladica P. Renal tumors: technical success and early clinical experience with radiofrequency ablation of 18 tumors. Cardiovasc Intervent Radiol 29 (2006) 202-209
22. Wagner A.A., Solomon S.B., and Su L.M. Treatment of renal tumors with radiofrequency ablation. J Endourol 19 (2005) 643-652
23. Park S., Anderson J.K., Matsumoto E.D., et al. Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol 20 (2006) 569-573
24. Hines-Peralta A., and Goldberg S.N. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 10 (2004) 6328S-6334S
25. Zagoria R.J. Imaging-guided radiofrequency ablation of renal masses. Radiographics 24 Suppl 1 (2004) S59-S71
26. Stern J.M., Park S., Anderson J.K., et al. Kidney tumor radiofrequency abaltion: experience in ASA I and ASA II patients. J Urol 175 (2006) 27 (abstract no. 81)
27. Matlaga B.R., Zagoria R.J., Woodruff R.D., et al. Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol 168 (2002) 2401-2405
28. Michaels M.J., Rhee H.K., Mourtzinos A.P., et al. Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol 168 (2002) 2406-2409
29. Rendon R.A., Kachura J.R., Sweet J.M., et al. The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol 167 (2002) 1587-1592
30. Walther M.M., Shawker T.H., Libutti S.K., et al. A phase 2 study of radio frequency interstitial tissue ablation of localized renal tumors. J Urol 163 (2000) 1424-1427
31. Klingler H.C., Mauermann J., Remzi M., et al. Skipping is still a common problem with radiofrequency ablation of small renal tumours. J Urol 175 (2006) 331-332 (abstract no. 1029)
32. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
33. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
34. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
35. Available at URL: http://www.medscape.com/viewprogram/5772_pnt. Accessed 2006.
36. Motzer R.J., Hutson T.E., Tomczak P., et al. Phaze III randomized trial of sunitnib malate (SU1 1248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 (2006) 2 (abstract no. LBA3)
37. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
38. Hudes G., Carducci M., Tomczak P., et al. A phaze III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alfa (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma. J Clin Oncol 24 (2006) 2 (abstract no. LBA4)
39. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388S-6392S
40. Escudier B., Szczylik C., Eisen T., et al. Randomised phase III trial of the multikinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur Urol Suppl 5 (2006) 287 (abstract no. 1058)